Poolbeg Pharma PLC (LON:POLB – Get Free Report) shares reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as GBX 7 ($0.09) and last traded at GBX 7.40 ($0.09), with a volume of 2840506 shares traded. The stock had previously closed at GBX 7.65 ($0.10).
Poolbeg Pharma Stock Up 4.2 %
The firm has a fifty day moving average of GBX 8.45 and a 200-day moving average of GBX 11.20. The firm has a market cap of £37.20 million, a P/E ratio of -747.00 and a beta of 2.11.
Poolbeg Pharma Company Profile
Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass broad spectrum RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis.
Featured Stories
- Five stocks we like better than Poolbeg Pharma
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- Best Aerospace Stocks Investing
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- The Most Important Warren Buffett Stock for Investors: His Own
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
